Awardee OrganizationCASE WESTERN RESERVE UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): Involucrin (hINV) acts as an important amine donor and is crosslinked to various amine acceptors by transglutaminase to assemble the cornified envelope. hINV is among the first proteins deposited and functions as a scaffolding for subsequent protein and lipid deposition. Appropriate hINV deposition is required for maintenance of barrier function. Involucrin expression is confined to external surface epithelial cells. It is expressed suprabasally in epidermis, and expression is altered in disease. To understand normal and abnormal epidermal differentiation, it is essential to understand the mechanisms that regulate epidermal gene expression. Involucrin is an advanced model for the study of gene regulatory mechanisms in epidermis. We are now positioned to address fundamental questions about the DNA sequences and transcription factor complexes that drive tissue-specific and differentiation-appropriate hINV expression in vivo. Our recent studies identify a region of the hINV gene upstream regulatory region, the distal regulatory region (DRR) that is required for differentiation-appropriate hINV gene expression. We have shown that the DRR contains spatially distinct elements that cooperate to regulate gene expression during differentiation. In addition, we have identified a specific AP1 site as a required participant in this regulation. We are now prepared to examine the composition of the multiprotein complex that forms at these sites and how this complex influences in vivo gene expression. The major goal of this proposal is to identify the transcription factors that bind within the DRR to regulate tissue-specific and differentiation-appropriate expression. These studies are designed to provide important new insights regarding the mechanisms that regulate gene expression during epidermal differentiation.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
077758407
UEI
HJMKEF7EJW69
Project Start Date
01-August-1993
Project End Date
30-June-2007
Budget Start Date
01-August-2005
Budget End Date
31-July-2006
Project Funding Information for 2005
Total Funding
$197,944
Direct Costs
$129,375
Indirect Costs
$68,569
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$197,944
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR041456-12
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR041456-12
Patents
No Patents information available for 5R01AR041456-12
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR041456-12
Clinical Studies
No Clinical Studies information available for 5R01AR041456-12
News and More
Related News Releases
No news release information available for 5R01AR041456-12
History
No Historical information available for 5R01AR041456-12
Similar Projects
No Similar Projects information available for 5R01AR041456-12